What is a stock summary page? Click here for an overview.
Business Description
PharmaSGP Holding SE
ISIN : DE000A2P4LJ5
Share Class Description:
XTER:PSG: Ordinary SharesCompare
Compare
Traded in other countries / regions
PSG.Germany IPO Date
2020-06-19Description
PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 62.12 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | 6.31 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 3.7 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.9 | |||||
| 3-Year EBITDA Growth Rate | 34.4 | |||||
| 3-Year EPS without NRI Growth Rate | 9.6 | |||||
| 3-Year FCF Growth Rate | 21 | |||||
| 3-Year Book Growth Rate | 51.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 17.57 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.38 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.06 | |||||
| 9-Day RSI | 37.08 | |||||
| 14-Day RSI | 39.61 | |||||
| 3-1 Month Momentum % | -1.6 | |||||
| 6-1 Month Momentum % | 5.13 | |||||
| 12-1 Month Momentum % | 13.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | |||||
| Quick Ratio | 1.9 | |||||
| Cash Ratio | 1.27 | |||||
| Days Inventory | 356.21 | |||||
| Days Sales Outstanding | 41.81 | |||||
| Days Payable | 384.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.67 | |||||
| Dividend Payout Ratio | 0.87 | |||||
| Forward Dividend Yield % | 5.67 | |||||
| 5-Year Yield-on-Cost % | 5.67 | |||||
| Shareholder Yield % | 5.79 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.94 | |||||
| Operating Margin % | 23.47 | |||||
| Net Margin % | 16.49 | |||||
| FCF Margin % | 25.08 | |||||
| ROE % | 49.33 | |||||
| ROA % | 14.08 | |||||
| ROIC % | 24.12 | |||||
| 3-Year ROIIC % | 8.48 | |||||
| ROC (Joel Greenblatt) % | 2477.61 | |||||
| ROCE % | 28.11 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.29 | |||||
| Forward PE Ratio | 12.83 | |||||
| PE Ratio without NRI | 15.29 | |||||
| Price-to-Owner-Earnings | 24.1 | |||||
| PS Ratio | 2.52 | |||||
| PB Ratio | 7.79 | |||||
| Price-to-Free-Cash-Flow | 10.02 | |||||
| Price-to-Operating-Cash-Flow | 9.51 | |||||
| EV-to-EBIT | 8.55 | |||||
| EV-to-EBITDA | 6.47 | |||||
| EV-to-Forward-EBITDA | 6.58 | |||||
| EV-to-Revenue | 2.21 | |||||
| EV-to-Forward-Revenue | 2.09 | |||||
| EV-to-FCF | 8.76 | |||||
| Price-to-GF-Value | 0.68 | |||||
| Earnings Yield (Greenblatt) % | 11.7 | |||||
| FCF Yield % | 9.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaSGP Holding SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 114 | ||
| EPS (TTM) (€) | 1.57 | ||
| Beta | 0.12 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 28.49 | ||
| 14-Day RSI | 39.61 | ||
| 14-Day ATR (€) | 0.46446 | ||
| 20-Day SMA (€) | 24.46 | ||
| 12-1 Month Momentum % | 13.89 | ||
| 52-Week Range (€) | 19 - 30 | ||
| Shares Outstanding (Mil) | 11.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaSGP Holding SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaSGP Holding SE Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmaSGP Holding SE Frequently Asked Questions
What is PharmaSGP Holding SE(XTER:PSG)'s stock price today?
The current price of XTER:PSG is €24.00. The 52 week high of XTER:PSG is €30.00 and 52 week low is €19.00.
When is next earnings date of PharmaSGP Holding SE(XTER:PSG)?
The next earnings date of PharmaSGP Holding SE(XTER:PSG) is .
Does PharmaSGP Holding SE(XTER:PSG) pay dividends? If so, how much?
The Dividend Yield %  of PharmaSGP Holding SE(XTER:PSG) is 5.67% (As of Today), Highest Dividend Payout Ratio of PharmaSGP Holding SE(XTER:PSG) was 0.87. The lowest was 0.37. And the median was 0.41. The  Forward Dividend Yield % of PharmaSGP Holding SE(XTER:PSG) is 5.67%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers